echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Tag Pharma plans to acquire part of the equity of Japanese EPS with us $17.7433 million!

    Tag Pharma plans to acquire part of the equity of Japanese EPS with us $17.7433 million!

    • Last Update: 2019-10-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On October 30, tag Pharma announced that its wholly-owned subsidiary, Hong Kong tag Pharma Technology Co., Ltd (hereinafter referred to as "Hong Kong tag") intends to raise about 1, US $7.7433 million purchase of 1.4 million ordinary shares of EPS ホ ー ルディン グ ス Co., Ltd (hereinafter referred to as "EPS"), which will be transferred to tag Hong Kong through the transfer of treasury shares After the completion of this transaction, Hong Kong Tiger will hold long-term equity of eps3.06% Announcement display, EPS was founded in May 1991, with legal representative of Hiro (Yan Hao); as of March 2019, its total assets were 67809 million yen; it is a company listed in the first branch (main board market) of Tokyo Stock Exchange, Japan, which mainly provides various high added prices for pharmaceutical companies, medical device manufacturers, new drug research and development companies, medical institutions, university research institutions and many other customers Value solution to support customer's product development It has accumulated rich experience in medicine, medical devices and other fields, and is a leading enterprise in the CrO (contract research organization) industry in Japan The core business of EPS is cro At the same time, its company extends its outsourcing business including SMO (site management organization), CSO (contract sales organization), etc., which can provide relevant services for domestic and foreign pharmaceutical companies and medical device manufacturers Tiger Pharma is a contract research organization (CRO) that focuses on providing professional services for the whole process of clinical trials for new drug research and development The company is headquartered in Hangzhou, with 33 subsidiaries It has global service outlets in 95 major cities in mainland China, Hong Kong, Taiwan, South Korea, Japan, Malaysia, Singapore, India, Australia, Canada, Switzerland, the United States, Romania and other places With more than 4000 international professional teams, it has successfully opened more than 600 global customers More than 1500 clinical trial services were exhibited Tiger pharmaceutical is also known as "innovative clinical cro" because it has participated in more than 160 domestic innovative drug clinical trials According to the sales data of the listed enterprises of yaozhi.com, since the beginning of 2010, the operating revenue of tag pharmaceutical has continued to rise, with a revenue of 2300659700 yuan and a net profit of 506797200 yuan in 2018 Meanwhile, R & D investment reached a record high in 2017, reaching 5861.38 In addition, it is worth noting that the market value of tag medicine has further increased since 2018, reaching 28.193 billion yuan in 2019 Under the current environment of domestic pharmaceutical innovation and reform, there is a lack of professional cro in China With the rapid growth of cro market, the prospect is huge, and the emergence of tag medicine has seized the opportunity of clinical trials of innovative drugs According to pharmaceutical intelligence data, since 2018, the market value of tag Pharma has further soared, reaching 28.193 billion yuan in 2019 Tag Pharma said that after the completion of this transaction, tag Pharma will establish a long-term cooperation relationship with EPS, which is conducive to the company's further expansion of business in the Asia Pacific Region and has a positive impact on its future operation, and the market value may further improve Information source: Announcement 37 of yaozhi.com and Taige pharmaceutical enterprise: This article is the integration content, the opinion only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.